February 27, 2020 | Deborah Kotz
Psychiatrist-Researcher Dr. Gloria Reeves Appointed to Serve as Vice Chair for Research
The new position will provide a centralized office for the coordination of research scholarship in the Department, which has 82 full-time faculty and a research base of $41 million in fiscal year 2019.
In her new role, Dr. Reeves will focus on supporting career development of faculty through grant writing and submissions, establishing a formalized mentorship program in the Department, and providing added support for the Department’s research education curriculum for residents.
In particular, Dr. Reeves will support junior and mid-level faculty members in their career development, as well as facilitate communication, connections, and collaborations within the Department, other UMB Schools and Departments, as well as other institutions.
Dr. Reeves joined the UMSOM faculty in 2002 after completing her medical, residency, and fellowship training, all at UMSOM. Her expertise is in pediatric psychopharmacology and obesity-related health issues among individuals with behavioral health disorders. She completed a National Institutes of Health-funded K12 career development award that was focused on state-of-the-art, obesity-related health assessments for youth and adults.
Dr. Reeves’ research team is structured to conduct “Family-Centered” research, which involves partnering and collaborating with consumers and community stakeholders in all phases of research – design, implementation, and dissemination. She is currently developing and testing a “Family Navigator” model to improve parent and child health outcomes through peer-delivered wellness strategies. Her research portfolio includes a total of $2.7 million in funding, from the National Institutes of Health and elsewhere, for fiscal year 2019.
Overall, the research portfolio of the Department of Psychiatry reflects a wide range of diverse clinical and basic science programs that span translational, educational, and psychiatric services, making significant contributions to scientific knowledge and the delivery of evidence-based care.
“There is a strong tradition of research in the Department of Psychiatry, with the longstanding Maryland Psychiatric Research Center and its nationally-recognized focus on schizophrenia,” said Dean Reece, who is and Executive Vice President for Medical Affairs at University of Maryland Baltimore and the John Z. and Akiko K. Bowers Distinguished Professor. “We look forward to the Department building on this legacy with a new generation of brain and psychiatric research that will advance knowledge and provide critical therapies for our patients.”
About the University of Maryland School of Medicine
Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 45 academic departments, centers, institutes, and programs; and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished two-time winner of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1.2 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically based care for nearly 2 million patients each year. The School of Medicine has more than $540 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total population of nearly 9,000 faculty and staff, including 2,500 student trainees, residents, and fellows. The combined School of Medicine and Medical System (“University of Maryland Medicine”) has an annual budget of nearly $6 billion and an economic impact more than $15 billion on the state and local community. The School of Medicine faculty, which ranks as the 8th highest among public medical schools in research productivity, is an innovator in translational medicine, with 600 active patents and 24 start-up companies. The School of Medicine works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu
Contact
Office of Public Affairs
655 West Baltimore Street
Bressler Research Building 14-002
Baltimore, Maryland 21201-1559
Contact Media Relations
(410) 706-5260
Deborah Kotz
Director of Media Relations
Office of Public Affairs & Communications
University of Maryland School of Medicine
o: 410-706-4255
c: 410-804-0054
t: @debkotz2
Related stories

Tuesday, May 10, 2022
Longtime Academic and Clinical Affairs Leader, Department Chair, and Faculty Member, Tony Lehman, MD, Announces Retirement
University of Maryland School of Medicine (UMSOM) Dean E. Albert Reece, MD, PhD, MBA, announced today that Anthony Lehman, MD, MSPH, who served the UMSOM for more than 30 years as Senior Associate Dean for Clinical Affairs, Department Chair, and distinguished faculty member in the UMSOM Department of Psychiatry, will retire, effective June 30, 2022.

Thursday, January 16, 2020
University of Maryland School of Medicine Research Shows That Older Patients With Untreated Sleep Apnea Need Greater Medical Care
Obstructive sleep apnea (OSA) is a common and costly medical condition leading to a wide range of health risks such as cardiovascular disease, stroke, depression, diabetes and even premature death. Researchers at the University of Maryland School of Medicine (UMSOM) found that the medical costs are substantially higher among older adults who go untreated for the disorder.

Wednesday, October 16, 2019
Researchers Discover Potential Therapy to Treat Detrimental Effects of Marijuana in Pre-Adolescent Individuals Exposed to THC in Womb
As a growing number of U.S. states legalize the medicinal and recreational use of marijuana, an increasing number of American women are using cannabis before becoming pregnant and during early pregnancy often to treat morning sickness, anxiety, and lower back pain. Although emerging evidence indicates that this may have long-term consequences for their babies’ brain development, how this occurs remains unclear.

Thursday, April 04, 2019
Mobile Addiction Treatment Unit Serves Maryland Eastern Shore
Health and addiction treatment officials from the Caroline County Health Department, Maryland Department of Health, the Maryland Opioid Operational Command Center, and the University of Maryland School of Medicine (UMSOM) in Denton, MD., launched the Eastern Shore Mobile Care Collaborative (ESMCC), a mobile system designed to provide state-of-the-art treatment for opioid disorders for those in need on the Maryland Eastern shore.

Wednesday, March 27, 2019
UMSOM Researchers Discover a Critical Receptor Involved in the Response to Fast-Acting Antidepressants Like Ketamine
Effective treatment of clinical depression remains a major mental health issue, with roughly 30 percent of patients who do not respond to any of the available treatments. Researchers at the University of Maryland School of Medicine (UMSOM) have discovered a crucial receptor called mGlu2 that is critical to the mechanism of fast-acting antidepressants such as ketamine when used to treat depression.

Tuesday, October 16, 2018
Bankole A. Johnson Receives Prestigious American Society of Addiction Medicine Award
Bankole Johnson, DSc, MD, the Dr. Irving J. Taylor Professor and Chair of the Department of Psychiatry at the University of Maryland School of Medicine (UMSOM), has been named to receive the American Society of Addiction Medicine’s (ASAM) R. Brinkley Smithers Distinguished Scientist Award.

Friday, January 05, 2018
Fighting Opioid Addiction from Baltimore to Garrett County: University of Maryland School of Medicine Rises to the Challenge
The opioid epidemic has been deadly for Maryland. In 2016, more than 2000 people in the state died from overdoses; in 2017, deaths rose another 40 percent, and deaths from the powerful synthetic opioid fentanyl were up nearly 140 percent. Last year, Gov. Larry Hogan declared a state of emergency in response to the opioid epidemic, saying the state needs an “all-hands-on-deck approach.”
Wednesday, June 07, 2017
Dr. Jill RachBeisel Named Vice Chair for Clinical Affairs in UM School of Medicine’s Department of Psychiatry
Bankole A. Johnson, DSc, MD, MBChB, The Dr. Irving J. Taylor Professor and Chair for the Department of Psychiatry, Professor of Pharmacology, Anatomy and Neurobiology, along with UM SOM Dean E. Albert Reece, MD, PhD, MBA, announced today that Jill RachBeisel, MD, Associate Professor of Psychiatry, has been named Vice Chair for Clinical Affairs for the UM SOM Department of Psychiatry, commencing at the start of the next academic year.